Safeguard Scientifics Q3 net income $0.9M, vs loss $3.2M; cash $15.7M

SAFEGUARD SCIENTIFICS INC

2023-Q3 EPS reported -$0.33

Q3 net income $0.9M ($0.06 diluted EPS) vs net loss $3.2M ($0.19 loss) in Q3 2022.
9M net loss narrowed to $5.4M ($0.33 loss) from $9.4M ($0.57 loss) year earlier.
Cash and equivalents $15.7M; carrying value of ownership interests $14.8M (cost $122.8M).
InfoBionic recap reduced ownership to ~5% with $1.7M non-cash gain; Trice Medical recap resulted in de minimis stake.
Aggregate trailing 12-month revenue of six portfolio companies $96M, up 10.3% YoY.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SAFEGUARD SCIENTIFICS INC reported the three and nine months ended September 30, 2023 results: net income Net income for the three months ended September 30, 2023 was $0.9 million, or $0.06 per basic and fully diluted share, a.

Period: the three and nine months ended September 30, 2023
Net income: Net income for the three months ended September 30, 2023 was $0.9 million, or $0.06 per basic and fully diluted share, a
Result: reported results

Exact text from the filing

o Net income for the three months ended September 30, 2023 was $0.9 million, or $0.06 per basic and fully diluted share, as compared with a net loss of $3.2 million, or $0.19 per basic and fully diluted share, for the same period in 2022.

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

SAFEGUARD SCIENTIFICS INC filing history →

Source: SEC EDGAR

accession 0001437749-23-030023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.